Recently, Long et al. highlighted a new therapeutic approach using a triplet of immune checkpoint blockade in newly diagnosed GBM, where the MGMT status might play an essential role in the response to this new combined therapeutic approach [36]. This evidence concerns the gene MGMT and glioblastoma.